Lexicon Pharmaceuticals, Inc. (NasdaqCM: LXRX)
Health Care · Pharmaceuticals · US
$1.68
-7.69% today · +12.8% 1Y
Lexicon Pharmaceuticals, Inc. (NasdaqCM: LXRX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $747.53M and employs 81 people.
Over the last twelve months the share price has gained 12.8%, trading between 1.10 and 2.68.
Tweenvest scores Lexicon Pharmaceuticals, Inc. across four factors: quality 35/100, value 67/100, growth 100/100. Its strongest factor is growth.
LXRX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $747.53M
- Revenue (TTM)
- $41.47M
- P/E
- —
- EPS
- -0.16
- Dividend yield
- —
- Beta (5Y)
- 1.08
- 52-week high
- $2.68
- 52-week low
- $1.10
- Avg volume (3M)
- —
- Shares outstanding
- 444.96M
- Employees
- 81
- Next earnings
- —
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
- ISIN
- US5288723027
- Founded
- 1995
- Listed since
- Apr 7, 2000
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| CHO Pharma, Inc.TPEX: 6586 | $773.05M | NT$115.50 | -0.86% |
| Guizhou Sanli Pharmaceutical Co.,LtdSHSE: 603439 | $758.35M | CN¥12.55 | -4.78% |
| Heilongjiang ZBD Pharmaceutical Co., Ltd.SHSE: 603567 | $756.62M | CN¥5.40 | +2.66% |
| DongKook Pharmaceutical Co., Ltd.KOSDAQ: A086450 | $751.63M | ₩22,400.00 | -1.54% |
| Knight Therapeutics Inc.TSX: GUD | $745.60M | CA$10.83 | +4.94% |
| Shandong Keyuan Pharmaceutical Co., Ltd.SZSE: 301281 | $743.37M | CN¥45.98 | -2.69% |
| Morepen Laboratories LimitedBSE: 500288 | $734.62M | Rs129.75 | -2.95% |
| Lionco Pharmaceutical Group Co.,Ltd.SHSE: 603669 | $731.05M | CN¥6.96 | +9.95% |
Figures last refreshed Oct 11, 2026.